Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Phase 2

Completed

Conditions: Chronic Plaque-type Psoriasis

Interventions: Procedure: Skin biopsies

First Posted Date: 2018-06-12

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03553823

Locations: 🇩🇪
Novartis Investigative Site, Selters, Germany

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Phase 3

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2018-06-11

Last Posted Date: 2025-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 552

Registration Number: NCT03551626

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)
Triple Negative Breast Cancer (TNBC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer Microsatellite Stable (MSS)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Other: NZV930
Other: PDR001
Drug: NIR178

First Posted Date: 2018-06-07

Last Posted Date: 2024-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT03549000

Locations: 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom
🇺🇸
University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: EFG816
Drug: erlotinib or gefitinib

First Posted Date: 2018-05-18

Last Posted Date: 2019-11-22

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03529084

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Phase 4

Completed

Conditions: Renal Angiomyolipoma

Interventions: Drug: Everolimus

First Posted Date: 2018-05-16

Last Posted Date: 2021-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03525834

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase 2

Completed

Conditions: Immune Thrombocytopenic Purpura (ITP)

Interventions: Drug: eltrombopag

First Posted Date: 2018-05-15

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03524612

Locations: 🇺🇸
Hematology Oncology Association of Rockland, Nyack, New York, United States
🇺🇸
Case Western Reserve, Cleveland, Ohio, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: ZPL389 50mg
Drug: ZPL389 10mg
Drug: Placebo
Drug: ZPL389 3mg
Drug: ZPL389 30mg

First Posted Date: 2018-05-07

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 293

Registration Number: NCT03517566

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: Tropifexor (LJN452)
Drug: Cenicriviroc (CVC)

First Posted Date: 2018-05-07

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 193

Registration Number: NCT03517540

Locations: 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Placebo
Drug: Midostaurin
Drug: Chemotherapy

First Posted Date: 2018-04-30

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 511

Registration Number: NCT03512197

Locations: 🇺🇸
University of Chicago Medical Center ., Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Oregon Health and Science Univ, Portland, Oregon, United States

and more 1 locations

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis

Interventions: Drug: secukinumab 150 mg

First Posted Date: 2018-04-20

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 331

Registration Number: NCT03504852

Locations: 🇷🇺
Novartis Investigative Site, Saratov, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy